{name}
{subtitle}
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
city
~30 mi. (Reims, France, +8 more cities)
facility
Hôpital Robert Debré, +1 more facility
drug
irinotecan, +1 more drug
drug type
chemotherapy, +1 more type
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
city
~30 mi. (Reims, France, +7 more cities)
facility
CHU de Reims
drug
lenvatinib, +1 more drug
drug type
Other, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~72 mi. (Saint-Quentin, France, +226 more cities)
facility
C.H. de Saint Quentin ( Site 0481)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~72 mi. (Saint-Quentin, France, +122 more cities)
facility
C.H. de Saint Quentin ( Site 1111)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~83 mi. (Yvoir, Belgium, +130 more cities)
facility
CHU UCL Namur Site de Godinne ( Site 0103)
drug
BCG solution, +1 more drug
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~83 mi. (Yvoir, Belgium, +207 more cities)
facility
CHU UCL Namur Site de Godinne ( Site 0706)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~83 mi. (Yvoir, Belgium, +159 more cities)
facility
CHU UCL Namur Site de Godinne ( Site 0354)
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type